BMRN BioMarin Pharmaceutical Inc.

61.42USD-0.02%Mkt Cap: 11.90B USDP/E: —

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, …

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap11.90B USD
Enterprise Value15.35B USD
Revenue (TTM)3.66B USD
Gross Profit2.50B USD
Net Income (TTM)348.90M USD
Revenue/Share18.95 USD
Last Price61.42 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees3.2K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)9.76
PEG0.56
EV/EBITDA17.96
EV/Revenue4.20
P/S3.25
P/B1.90
EPS (TTM)-0.10 USD
EPS (Forward)6.32 USD
52W Range
49.2656% of range70.98
52W High70.98 USD
52W Low49.26 USD
Profitability
Gross Margin77.73%
Oper. Margin16.34%
EBITDA Margin23.39%
Profit Margin10.83%
ROE5.73%
ROA4.59%
ROIC5.77%
ROCE5.99%
Growth
Revenue Growth32.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF827.99M USD
CapEx (TTM)110.97M USD
FCF Margin-0.44%
FCF Yield-0.13%
Net Debt3.45B USD
Net Debt/EBITDA4.04
Net Debt/FCF—
Balance Sheet
Debt/Equity0.10
Current Ratio2.44
Quick Ratio1.13
Book Value/Sh32.30 USD
Cash/Share3.80 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)90.30 USD
Upside (mean)+47.0%
Target Range60.00 USD – 120.00 USD
60.00+47.0% to mean120.00
# Analysts27
Ownership
Shares Out.193.69M
Float192.75M
Insiders0.38%
Institutions103.13%
Short Interest
Short Ratio5.7d
Short % Float7.31%
Short % Out.7.29%
Shares Short14.12M
Short (prev mo.)11.52M
Technical
SMA 5058.69 (+4.7%)
SMA 20058.47 (+5.0%)
Beta0.23
S&P 52W Chg12.08%
Avg Vol (30d)2.52M
Avg Vol (10d)2.34M
Technical Indicators
RSI (14)64.1
MACD0.5816
MACD Signal-0.0533
MACD Hist.+0.6349
BB Upper60.75 USD
BB Middle57.37 USD
BB Lower53.99 USD
BB Width11.79%
ATR (14)1.978 USD
Vol Ratio (20d)2.21x

About BioMarin Pharmaceutical (NASDAQ: BMRN)

›

BioMarin Pharmaceutical (NASDAQ: BMRN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3,221 employees.

The shares were at 61.42 USD on 19 November 2026, up 18.5% over 52 weeks. Its 52-week range is 49.26 USD to 70.98 USD: the price is 13.5% below the high and 24.7% above the low.

Its market capitalisation is 11.90B USD.

BioMarin Pharmaceutical reports return on equity of 5.7%, an operating margin of 16.3% and revenue up 32.0% year over year.

Its debt exceeds its cash by 3.45B USD, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 90.30 USD is 47.0% above the current price. The next earnings report is expected on 22 February 2027.